Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

Taiwan ,Japan ,United States ,Hong Kong ,Suzhou ,Jiangsu ,China ,Henan ,Macau ,Chinese ,Innovent Biologics ,Hongwei Jiang ,Adimab Incyte ,Eli Lilly ,Wenying Yang ,Nature Communications ,Clinical Development Of Innovent ,Company Lilly ,Prnewswire Innovent Biologics Inc ,Md Anderson Cancer Center ,Innovent Or Company ,Incyte Corporation ,Innovent Biologics Inc ,First Affiliated Hospital ,Henan University ,China Japan Friendship Hospital ,Lei Qian ,Vice President ,Clinical Development ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Mainland China ,